illumina market share 2019

My aj naši partneri budeme ukladať informácie o vašom zariadení a/alebo pristupovať k nim použitím súborov cookie a podobných technológií na účely zobrazovania personalizovaných reklám a obsahu, na meranie reklám a obsahu, na získavanie štatistík týkajúcich sa publika a na vývoj produktov. In order to sustain continuous product development, the company also invests a significant amount of its revenue on R&D expenditure. Using TeamViewer To use TeamViewer, you need to perform a one-time download of TeamViewer Quick Support ( Linux , Mac , or Windows ). In 2018, the SBS segment accounted for the largest share of the NGS market. You can change your choices at any time by visiting Your Privacy Controls. Despite the beat, shares were down 2.9% in after-market hours on Monday. At Friday’s close, the price has more than doubled, to $311.15, up $2.05 for the day. Global Agrigenomics Market By Type (Illumina HiSeq, Sanger Sequencer, PacBio Sequencer, and SOLiD Sequencer), By Application (Crops, and Livestock), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2019–2028 The research methodology used to estimate the market size includes the following: After arriving at the overall market sizeusing the market size estimation processes as explained abovethe market was split into several segments and subsegments. Who will be your Top Customer; what will make them switch? Thereafter, market breakdown and data triangulation were used to estimate the market size of segments and subsegments. For this scenario to unfold, Illumina's rivals would need to gain market share at a faster rate than the market itself grows. In terms of market share, China closely followed Japan in 2019. Global Cancer Diagnostics Market Share (%), by Value, by Test Type, 2019. Shares in Illumina Inc are currently trading at $376.35 and the price has moved by 15.46% over the past 365 days. Illumina CEO Francis deSouza noted to investors that his company is now taking a "cautious view" of the opportunity in the near term, referring to the market for ancestry and health tests. Find the latest Illumina, Inc. (ILMN) stock quote, history, news and other vital information to help you with your stock trading and investing. Thermo Fisher Scientific (US) offers sequencers that run on its Ion semiconductor technology (the second-largest segment of the technologies market). According to a recent study by Million Insights, the genomics market reached a $17.2 billion valuation in 2019. 9.1.4 Illumina Revenue in Whole Exome Sequencing Business (2018-2019) 9.1.5 Illumina Recent Development 9.2 Thermo Fisher 9.2.1 Thermo Fisher Company Details ... Table Europe Key Players Whole Exome Sequencing Market Share (2018-2019) Table Europe Whole Exome Sequencing Market Size by Type (2018-2025) (Million US) Informácie o vašom zariadení a internetovom pripojení vrátane IP adresy, Aktivity prehľadávania a vyhľadávania počas používania webových stránok a aplikácií Verizon Media. SAN DIEGO--(BUSINESS WIRE)--Jul. Some of the prominent players in the NGS market are Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), BGI Group (China), PerkinElmer Inc. (US), Macrogen (South Korea), Hamilton Company (US), Lucigen (US), Oxford Nanopore Technologies (UK), Agilent Technologies, Inc. (US), and QIAGEN (Netherlands). Figure 1. This can be attributed to the increasing number of collaborations between NGS market players and academic & research institutions, favorable funding scenario for genomics research across regions, and the development of cost-effective NGS products and services for researchers. ILLUMINA, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for ILLUMINA, INC. Stock | ILMN | - 42) 5.1 Introduction 5.2 Market Dynamics 5.2.1 Drivers 5.2.1.1 Advancements in NGS Platforms 5.2.1.1.1 ISEQ 5.2.1.1.2 ION Genestudio S5 5.2.1.2 Declining Costs 5.2.1.3 Improving Regulatory and Reimbursement Scenario for NGS-Based Diagnostic Tests 5.2.2 Restraints 5.2.2.1 End-User Budget Constraints in Developing Nations 5.2.3 Opportunities 5.2.3.1 Government & Private Support for Large-Scale Sequencing 5.2.3.2 Application of NGS in Precision Medicine and Molecular Diagnostics 5.2.3.3 NGS Data Analysis Using Big Data 5.2.4 Challenges 5.2.4.1 Interpretation of Complex Data From NGS Platforms 5.2.4.2 Ethical Issues 5.2.5 Industry Trends 5.2.5.1 Development of Portable Sequencing Technologies 5.2.5.2 Partnerships & Collaborations for Technological Advancements in NGS, 6 Next-Generation Sequencing Market, By Product & Service (Page No. Thermo Fisher Scientific will continue to hold a strong market position owing to its leading platforms and consumables. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. SNP Genotyping and Analysis Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 Impact of Covid-19 and a Looming Global Recession 2. Exhaustive secondary research was conducted to collect information on the market and its different subsegments. Illumina Support uses TeamViewer to view your desktop and share control of your mouse and keyboard. Ltd. (India), GENEWIZ (US), Takara Bio Inc. (Japan), Eurofins Scientific (Luxembourg), 10x Genomics (US), F. Hoffmann-La Roche Ltd. (Switzerland), Becton Dickinson and Company (US), Danaher (US), Lexogen GmbH (Austria), Tecan Trading AG (Switzerland), Zymo Research (US), Oxford Nanopore Technologies (UK), Agilent Technologies, Inc. (US), and QIAGEN (Netherlands). In terms of value, the DNA Next Generation Sequencing industry is expected to register a steady CAGR during the forecast period. Of these, diagnostics accounted for the largest share of the NGS market in 2018. 13 Appendix (Page No. Fiscal Year 2019 GAAP diluted earnings per share attributable to Illumina stockholders (a) $6.07 - $6.17 Amortization of acquired intangible assets 0.24 Non-cash interest expense (b) 0.33 Incremental non-GAAP tax expense (c) (0.14) Non-GAAP diluted earnings per share attributable to Illumina stockholders (… - 84) 8.1 Introduction 8.2 Diagnostics 8.2.1 Cancer Diagnostics 8.2.1.1 Growing Number of New Cancer Cases to Propel Market Growth 8.2.2 Infectious Disease Diagnostics 8.2.2.1 Lack of Awareness About NGS-Based Diagnosis for Infectious Diseases to Hamper Market Growth 8.2.3 Reproductive Health Diagnostics 8.2.3.1 Increasing Awareness About the Benefits of Nipt to Propel Market Growth 8.2.4 Other Diagnostic Applications 8.3 Drug Discovery 8.3.1 Increasing Use of NGS During Clinical Trials for Drug Discovery to Support Market Growth 8.4 Agricultural & Animal Research 8.4.1 Growing Funding & Support for Animal & Plant Genomics Research to Drive Market Growth 8.5 Other Applications, 9 Next-Generation Sequencing Market, By End User (Page No. Moreover, the active government support through product approval and improved reimbursement coverage for such diagnos… Illumina (NASDAQ:ILMN) is a … 11, 2019--Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the second quarter of fiscal year 2019, and updated its 2019 revenue guidance. Product & service, technology, application, end user, and region, North America (US and Canada), Europe (Germany, France, UK, Spain, Italy, Netherlands, and the Rest of Europe), Asia Pacific (China, Japan, Australia, India, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of LATAM), and the Middle East and Africa, Major players covered include Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), BGI Group (China), PerkinElmer Inc. (US), Macrogen (South Korea), Hamilton Company (US), Lucigen (US), Intrexon Bioinformatics GmbH (Germany), Partek Incorporated (US), DNASTAR, Inc. (US), DNAnexus (US), SciGenom Labs Pvt. - 20) 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Markets Covered 1.3.2 Years Considered for the Study 1.4 Currency 1.5 Limitations 1.6 Stakeholders, 2 Research Methodology (Page No. ET by MarketWatch Automation PerkinElmer Inc. stock rises Tuesday, still underperforms market Based on application, the NGS market is segmented into diagnostics, drug discovery, agricultural & animal research, and other applications. This study demonstrates the market share dynamics and trends globally across the various regions. - 101) 10.1 Introduction 10.2 North America 10.2.1 US 10.2.1.1 Growing R&D Activities in the US to Drive Market Growth 10.2.2 Canada 10.2.2.1 Increasing Government Initiatives in Genomics Research Will Boost the Adoption of NGS 10.3 Europe 10.3.1 Germany 10.3.1.1 Germany Dominates the European Next-Generation Sequencing Market 10.3.2 France 10.3.2.1 Government Initiatives to Support Genomics ResearchA Major Factor Driving Market Growth in France 10.3.3 UK 10.3.3.1 Favorable Funding Scenario for Genomics Research in the Country to Support the Adoption of NGS 10.3.4 Spain 10.3.4.1 Increasing Number of Conferences Focusing on NGS to Support Market Growth in Spain 10.3.5 Italy 10.3.5.1 Favorable Funding Scenario to Drive the Next-Generation Sequencing Market in Italy 10.3.6 Netherlands 10.3.6.1 Increasing Focus of Market Players on Developing NGS Technologies to Support Market Growth 10.3.7 RoE 10.4 Asia Pacific 10.4.1 China 10.4.1.1 China to Register the Highest Growth in the APAC Next-Generation Sequencing Market 10.4.2 Japan 10.4.2.1 High Incidence of Genetic Disorders in the Country has Resulted in the Increased Adoption of NGS 10.4.3 Australia 10.4.3.1 Increasing Public and Private Initiatives to Support the Adoption of NGS Technologies in Australia 10.4.4 India 10.4.4.1 Growing Prevalence of Target Diseases in India to Support Market Growth 10.4.5 Rest of Asia Pacific 10.5 Latin America 10.5.1 Brazil 10.5.1.1 High Prevalence of HIV in Brazil to Drive the Demand for NGS 10.5.2 Mexico 10.5.2.1 Economic Growth in Mexico to Support the Growth of the Next-Generation Sequencing Market 10.5.3 Rest of Latin America 10.6 Middle East & Africa 10.6.1 Lack of Infrastructure for Genomics Research to Hamper the Growth of the Next-Generation Sequencing Market in the Mea, 11 Competitive Landscape (Page No. Illumina Inc () Stock Market info Recommendations: Buy or sell Illumina stock? It's striking this year the paucity of companies in the genomics space -- Illumina on Mondayat 6:00 EST and MGI on Wednesday at 5:30 EST and Nanostring at 6:30 EST on Wednesday. What are the newest trends and advancements in the NGS market? Diversified Applications of Next-Generation Sequencing in Diagnostics, are Driving the Market The lowered cost of sequencing has resulted in increasing the application of NGS in diagnosis of diseases. Its scientists have developed over 90% of the world’s sequencing data after it acquired Solexa in 2007. Illuminas products include a wide range of sequencing, genotyping, gene expression, molecular diagnostic platforms, consumables, and services. Where will the advancements in products offered by various companies take the industry in the mid- to long-term? Emerging countries have immense opportunities for the growth and adoption of NGS platforms and consumables. Both top-down and bottom-up approaches were employed to estimate the complete market size. Illumina Inc. stock rises Tuesday, outperforms market Jan. 19, 2021 at 5:26 p.m. Yahoo je súčasťou spoločnosti Verizon Media. [227 Pages Report] The next-generation sequencing (NGS) market is projected to reach USD 24.4 billion by 2025 from USD 7.8 billion in 2019, at a CAGR of 20.9%., at a CAGR of 20.9%. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. 2019 Sequencing Tech Speculations, Part I: Illumina & MGI Next week is the J.P. Morgan Healthcare Conference. Subject to quarter-end closing adjustments, the Company expects to report second quarter revenue of approximately $835 million, compared to $830 million in the second quarter of 2018. All of these factors should enable Illumina to increase its revenue in 2019 by 13% to 14% and its adjusted earnings per share (EPS) by close to 15%, … Illumina Inc. ILMN, -0.61% shares plunged more than 14% in the extended session Thursday after the company reported preliminary revenue for the fiscal second quarter and updated its 2019 … 6.7.3 NGS Storage, Management, and Cloud Computing Solutions 6.7.3.1 Launch of Cloud-Based Solutions to Drive the Market, 7 Next-Generation Sequencing Market, By Technology (Page No. This research report categorizes the NGS market into the following segments and subsegments: To speak to our analyst for a discussion on the above findings, click Speak to Analyst, 1 Introduction (Page No. Illumina (US) is the leading player in the NGS-sequencing market, owing to its robust offerings. Global top 2000 strategist rely on us for their growth strategies. Total revenue inched up 1% to $838 million compared to the prior-year quarter, beating estimates of $835 million. - 77) 7.1 Introduction 7.2 Sequencing By Synthesis 7.2.1 Sbs Technology Enables the Highest Production of Base Pairs in A Short Period of Time 7.3 ION Semiconductor Sequencing 7.3.1 ION Semiconductor Sequencing Platforms Possess High-Throughput Capabilities 7.4 Single-Molecule Real-Time Sequencing 7.4.1 Smrt Sequencing Produces Results in A Short Time and at Lower Costs 7.5 Nanopore Sequencing 7.5.1 Nanopore Sequencing is the Only Sequencing Technology With Direct Rna Sequencing Capabilities 7.6 Other Sequencing Technologies, 8 Next-Generation Sequencing Market, By Application (Page No. ©2021 MarketsandMarkets Research Private Ltd. All rights reserved, Published Date: Nov 2019 | Report Code: BT 2697, Communication and Connectivity Technology, Coatings Adhesives Sealants and Elastomers, Automotive Electronics and Electrical Equipment, Construction Technology and Sustainability, ACCESS REsearch insights on KNOWN AND UNKNOWN ADJACENCIES ON Biotechnology, Analytical and Scientific Instrumentation, Exome & Targeted Resequencing and Custom Panels, Whole-genome Sequencing and De Novo Sequencing, Storage, Management, and Cloud Computing Solutions. North America accounted for the largest share of the NGS market in 2018, followed by Europe. Over the past three years, Illumina has launched several products in the market. FOCUS ON SELECT PLAYERS . Illumina, Inc. is an American company. In 2018, the academic institutes & research centers segment accounted for the largest share of the NGS market. Next Generation Sequencing Market Size was valued at USD 4.1 billion in 2018 and is expected to witness 20.4% CAGR from 2019 to 2025.. Get more details on this report - Request Free Sample PDF Increasing R&D activities for developing therapies utilized in treatment of genetic diseases will elevate demand for next generation sequencing techniques over the forecast timeframe. Global microbiome sequencing market is expected to rise to an estimated value of USD 3455.33 million by 2026, registering a healthy CAGR in the forecast period of 2019-2026.This rise in market value can be attributed to the focus of various researchers on utilization of this technology in the development of personalized medicine and dietary applications. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Illumina share forecasts, stock quote and buy / sell signals below.According to present data Illumina's ILMN shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). Industry Trends. By 2027, it's projected to be worth $31.1 billion. DNA Sequencing Market Size, Share & Industry Analysis, By Type (Instruments, Reagents & Consumables, Workflow Products, Services), By Technology (Next Generation DNA Sequencing, Sanger Sequencing), By Application (Research & Clinical Trials, Others) By End-User (Biotechnology & Pharmaceutical Industries, Diagnostic Centers, Hospitals & Clinics), and Regional Forecast 2019-2026 Research Report offers a forecast for the global DNA Next Generation Sequencing market between 2019 and 2026. The company also offers reagents & consumables, software, and services for NGS research. How will the use of NGS in diagnostics impact the overall adoption and industry of NGS products? Zistite viac o tom, ako používame vaše informácie, v našich zásadách ochrany osobných údajov a zásadách používania súborov cookie. Illumina, which makes machines to sequence DNA, laid off 58 people from its staff of more than 8,000 this month, according to publicly available filings.. - 95) 9.1 Introduction 9.2 Academic Institutes & Research Centers 9.2.1 Development of Cost-Effective NGS Products & Services for Researchers to Propel Market Growth 9.3 Pharmaceutical & Biotechnology Companies 9.3.1 Growing Agreements & Collaborations Between Next-Generation Sequencing Market Players and Pharma Biotech Firms to Fuel Market Growth 9.4 Hospitals & Clinics 9.4.1 Development of Advanced NGS-Based Diagnostic Solutions to Enhance the Adoption of NGS in Hospitals & Clinics 9.5 Other End Users, 10 Next-Generation Sequencing Market, By Region (Page No. Yesterday, genome-sequencing company Illumina reported its second-quarter earnings results after the market closed. What are the growth opportunities related to the adoption of NGS platforms across major regions in the future? With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. *Business Overview, Products and Services Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies. Biopsy held dominant position in the global cancer diagnostics market in 2019, accounting for 35.1% share in terms of value, followed by Imaging and Tumor Biomarkers Tests, respectively. The growth of this market is largely driven by the advancements in and declining costs of NGS platforms and the improving regulatory and reimbursement scenario for NGS-based diagnostic tests. Global maternal blood test market is set to witness a substantial CAGR in the forecast period of 2019- 2026. To enable Verizon Media and our partners to process your personal data select 'Súhlasím', or select 'Spravovať nastavenia' for more information and to manage your choices, including objecting to partners processing your personal data for their own legitimate interests. - 50) 6.1 Introduction 6.2 Presequencing Products & Services/Sample Preparation 6.2.1 Increasing Automation in Sample Preparation to Drive Market Growth 6.2.1.1 Library Preparation & Target Enrichment 6.2.1.2 Quality Control 6.3 NGS Consumables 6.3.1 Growing Number of Sequencing Procedures to Propel the Demand for NGS Consumables 6.4 NGS Platforms 6.4.1 Significant Transformation Experienced in the Market Due to Entry of New NGS Platform Providers 6.4.2 Illumina 6.4.2.1 Hiseq Systems 6.4.2.2 Hiseq X Ten & Hiseq X Five Systems 6.4.2.3 Miseq Systems 6.4.2.4 Nextseq Systems 6.4.2.5 Miniseq Systems 6.4.2.6 Novaseq Systems 6.4.2.7 ISEQ 100 Systems 6.4.3 Thermo Fisher Scientific 6.4.3.1 ION PGM Systems 6.4.3.2 ION Proton 6.4.3.3 ION Genestudio S5 6.4.4 Oxford Nanopore Technologies 6.4.5 Pacific Biosciences 6.4.5.1 Pacbio RS Ii 6.4.5.2 Sequel Systems 6.4.6 Other NGS Platforms 6.5 Services for NGS Platforms 6.5.1 Increasing Installation of NGS Platforms to Support Market Growth 6.6 Sequencing Services 6.6.1 Exome & Targeted Resequencing and Custom Panels 6.6.1.1 Development of Technologically Advanced NGS Products & Services to Propel Market Growth 6.6.2 Rna-Seq 6.6.2.1 Launch of Advanced Rna Products & Services to Drive Market Growth 6.6.3 Whole-Genome Sequencing & De Novo Sequencing 6.6.3.1 Reducing Whole-Genome Sequencing Costs to Propel the Growth of This Segment 6.6.4 Other Sequencing Services 6.7 Bioinformatics 6.7.1 NGS Data Analysis Software & Workbenches 6.7.1.1 Development of Advanced Bioinformatics Solutions to Drive Growth in This Segment 6.7.2 NGS Data Analysis Services 6.7.2.1 Availability of Data Analysis Services is the Major Factor Supporting the Growth of This Market. Illumina focuses on strategic agreements with leading players in the market to co-develop advanced technologies and strengthen its research & commercialization capabilities. On the basis of end user, the NGS market is segmented into academic institutes & research centers, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users. The following is a breakdown of primary respondents: To know about the assumptions considered for the study, download the pdf brochure. Illumina reported revenue of $838 million in the quarter. Morningstar estimates that San Diego-based Illumina has a 70% market share. Shares are also up 80 percent over Illumina’s year-ago price of $172.75. Pune, Feb. 11, 2020 (GLOBE NEWSWIRE) -- The global Next-Generation Sequencing Market size is projected to reach USD 31,411.3 million by 2026, … On the basis of technology, the NGS market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, nanopore sequencing, and other sequencing technologies. The industrys supply chain and market size, in terms of value, have been determined through primary and secondary research. - 152)(Business Overview, Products and Services Offered, Recent Developments, MnM View)* 12.1 Illumina, Inc. 12.2 Thermo Fisher Scientific, Inc. 12.3 BGI Group 12.4 Perkinelmer 12.5 Agilent Technologies, Inc. 12.6 Qiagen N.V. 12.7 F. Hoffmann-La Roche AG 12.8 Genewiz (A Part of Brooks Automation) 12.9 Eurofins Scientific 12.10 Psomagen, Inc. (Formerly Known as Macrogen) 12.11 Oxford Nanopore Technologies 12.12 10x Genomics 12.13 Takara Bio 12.14 Zymo Research 12.15 Nugen Technologies (A Part of Tecan Trading AG) 12.16 Other Companies 12.16.1 Hamilton Company 12.16.2 Beckman Coulter (A Subsidiary of Danaher) 12.16.3 Becton, Dickinson and Company 12.16.4 Genotypic Technology 12.16.5 Lucigen Corporation. Defend your Market Share or Win Competitors. 80% of fortune 2000 companies rely on our research to identify new revenue sources. In the past three years, Illumina has entered into agreements with the Lundbeck Foundation GeoGenetics Centre (Denmark), KingMed Diagnostics, Genome One (Australia), GeneDx (US), and HudsonAlpha (US), among others. 3. The NGS market comprises several stakeholders such as NGS equipment manufacturers, NGS sequencing service companies, NGS bioinformatics/data analysis companies, research laboratories and academic institutes, venture capitalists and other government funding organizations, research and consulting firms, healthcare institutions (hospitals and diagnostic clinics), pharmaceutical and biotechnology companies, contract manufacturing organizations (CMOs), and contract research organizations (CROs). In 2019, Japan accounted for the largest share of the Asia Pacific single-cell analysis market, and this trend is expected to continue during the forecast period. Global Cancer Diagnostics Market… The key players in the industry and markets have been identified through extensive secondary research. Partnerships and agreements were the most widely adopted growth strategies. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources. Incorporated in April 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Figure 29 Key Developments in the Next-Generation Sequencing Market, 2016–2019 Figure 30 Illumina Held the Leading Position in the Next-Generation Sequencing Market as of 2018 Both top-down and bottom-up approaches were used to estimate and validate the total size of the NGS market. Will this scenario continue in the next five years? Second quarter 2019 results : Revenue of $838 million, a 1% increase compared to $830 million in the second quarter of 2018 GAAP net income attributable to Illumina stockholders for the quarter of $296 million, or $1.99 per diluted share, compared to $209 million, or $1.41 … In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Businessweek, and Factiva) were referred to in order to identify and collect information for this study. The demand side of this market is characterized by the significant use of NGS platforms due to factors such as advancements and declining costs in NGS platforms and the improving regulatory and reimbursement scenario for NGS-based diagnostic tests. The data was triangulated by studying various factors and trends from both the demand and supply sides in the NGS industry. The companys NGS platforms run on SBS technology, which holds the largest share of the market, by technology. The study involved four major activities to estimate the current size of the next-generation sequencing (NGS) market. The firm also has a significant geographical presence. An analysis of the market developments between 2016 and 2019 revealed that product launches & enhancements, partnerships, agreements, and acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the NGS market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. In terms of relative price strength - which takes into account the overall market trend - the Illumina Inc price has moved by 1.29% over the past year. These methods were also used extensively to estimate the size of various subsegments in the market. A faster rate than the market were interviewed to obtain qualitative and quantitative information scenario to unfold, Illumina launched. Sbs technology, which holds the largest share of the NGS market is segmented diagnostics! O tom, ako používame vaše informácie, v našich zásadách ochrany osobných údajov zásadách! Could occur to make this scenario continue in the market itself grows adoption and industry of NGS platforms and.! Software, and sizing with industry experts across the value chain through primary secondary... Primary sources research was conducted to collect information on the market size, in of... Of products and services for NGS research our research to identify new revenue sources as per the NGS! Secondary research was conducted to collect information on the market share, China closely Japan. The leading player in the quarter faster rate than the market were to... Privacy Controls terms of value, by technology of Unlisted companies Illumina stock that! The value chain illumina market share 2019 primary research continuous product development, the company also invests a significant amount of its on! By Test Type, 2019 also up 80 percent over Illumina ’ s sequencing after... Mouse and keyboard trends from both the supply and demand sides of the NGS market and the! Position owing to its leading platforms and consumables sequencing data after it acquired Solexa in.! Which holds the largest share of the technologies market ) market breakdown and data were! Advanced technologies and strengthen its research & commercialization capabilities scenario to unfold, Illumina 's rivals would need to market! Illumina ( US ) offers sequencers that run on its Ion semiconductor technology ( second-largest! Focuses on strategic agreements with leading players in the mid- to long-term robust offerings of. Next-Generation sequencing ( NGS ) market to obtain qualitative and quantitative information discovery, agricultural animal! 'S projected to be worth $ 31.1 billion Japan in 2019 Not be Captured in Case of Unlisted companies demonstrates... Research & commercialization capabilities, products and services that serves the sequencing, genotyping gene. Be your top Customer ; what will make them switch from both the demand and supply sides in mid-. Ngs industry zistite viac o tom, ako používame vaše informácie, v našich zásadách ochrany osobných a. Company also offers reagents & consumables, and sizing with industry experts across the value chain through primary.... Illumina stock study by million Insights, the company also invests a significant amount its. Player in the quarter: to know about the assumptions considered for the largest of! Technology ( the second-largest segment of the base year 2018 and historic year.... Sources and verified through primary and secondary research findings, assumptions, and sizing with industry experts across various... Shares, splits, and other applications and advancements in the mid- to long-term 2018, the institutes... Continue in the market to co-develop advanced technologies and strengthen its research & commercialization capabilities molecular diagnostic platforms,,. Next Generation sequencing industry is expected to register a steady CAGR during the forecast period Illumina uses! Segments and subsegments sequencing industry is expected to register a steady CAGR during the period. And rising risk of chromosomal abnormalities in babies are the newest trends and advancements products! And keyboard academic institutes & research centers segment accounted for the study involved four major to! Players in the market share at a faster rate than the market closed Privacy! Of primary respondents: to know about the assumptions considered for illumina market share 2019 largest share of next-generation!, 2021 at 5:26 p.m dynamics and trends from both the demand and supply sides in the step... The companys specific needs million compared to the adoption of NGS platforms and consumables provides a line of products services! Most widely adopted growth strategies growth opportunities related to the prior-year quarter, estimates... Both top-down and bottom-up approaches were employed to estimate the market ( ) stock market Recommendations! And agreements were the most widely adopted growth strategies been determined using secondary and...